<DOC>
	<DOCNO>NCT00066417</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy total-body irradiation donor peripheral stem cell transplant help stop growth cancer abnormal cell help stop patient 's immune system reject donor 's stem cell . When stem cell related donor , exactly match patient 's blood , infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . PURPOSE : This phase II trial study well peripheral stem cell transplant work treat patient high-risk leukemia .</brief_summary>
	<brief_title>Peripheral Stem Cell Transplant Treating Patients With High-Risk Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety preparative regimen comprise total body irradiation , cyclophosphamide , thiotepa , fludarabine , without anti-thymocyte globulin , patient high-risk leukemia treat peripheral blood stem cell transplantation partially match related donor . - Determine incidence graft failure , acute graft-versus-host disease ( GVHD ) , treatment-related mortality patient treat regimen . - Determine rate chronic GVHD relapse patient treat regimen . - Determine disease-free overall survival patient treat regimen . OUTLINE : This pilot study . Patients receive preparative regimen comprise total lymphoid irradiation daily day -13 -11 ; cyclophosphamide IV 1 hour day -8 -7 ; thiotepa IV 4 hour every 12 hour day -6 ; fludarabine IV 30 minute day -5 -1 ; total body irradiation day -1 . Patients also receive cyclosporine IV 12 hour day -8 -1 methylprednisolone IV twice daily day -3 -2 . Patients receive CD34-enriched T-cell-depleted allogeneic stem cell infusion day 0 . Patients disease progression uncontrolled infection without grade II great graft-versus-host disease may receive 3 donor lymphocyte infusion least 4 week apart disease regression . Patients follow least weekly day 100 6 , 12 , 18 , 24 , 36 , 48 month . PROJECTED ACCRUAL : A total 20-51 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Highrisk myelodysplastic syndrome ( MDS ) , meet 1 follow criterion : Transformation acute leukemia define least 15 % blast Secondary prior treatment chemotherapy and/or radiotherapy Presence complex cytogenetics ( least 3 karyotypic abnormality ) Monosomy deletion chromosome 7 Acute myeloid leukemia ( AML ) , meet 1 follow criterion : Highrisk AML first remission meeting 1 follow criterion : At least 3 karyotypic abnormality Monosomy deletion chromosome 5 7 = 11q23 chromosomal abnormality Prior diagnosis MDS Received prior radiotherapy chemotherapy In second subsequent remission Primary induction failure partial remission Untested sensitive relapse Chronic myelogenous leukemia , meet 1 follow criterion : Blast crisis Accelerated phase disease fail prior treatment imatinib mesylate , defined failure achieve hematologic response 3 month standard dose ( 600 mg/day ) therapy disease progression therapy Myeloproliferative disease The following diagnosis eligible : Agnogenic myeloid metaplasia Essential thrombocythemia Polycythemia vera Must evidence transformation acute leukemia Acute lymphocytic leukemia ( ALL ) , meet 1 follow criterion : Highrisk ALL first remission define 1 following : ( 9 ; 22 ) 11q23 chromosomal abnormality Complete response least 4 week induction therapy OR require least 2 induction regimen Second subsequent remission No relapse leukemia refractory appropriate salvage therapy Availability HLAmismatched family donor Donor age 75 No good donor alternative ( i.e. , HLAmatched relate unrelated stem cell donor ) available PATIENT CHARACTERISTICS : Age 10 50 Performance status ECOG 01 Life expectancy More 3 month Hematopoietic See Disease Characteristics Hepatic Bilirubin great 4 mg/dL Transaminases great 3 time upper limit normal Renal Creatinine great 2.0 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular LVEF least 40 % Pulmonary DLCO least 65 % predict Other Not pregnant Negative pregnancy test HIV negative No prior malignancy except basal cell squamous cell skin cancer remote history cancer consider cure No major organ dysfunction would preclude transplantation No major anticipate illness organ failure would preclude transplantation No severe psychiatric illness mental deficiency would preclude give informed consent comply study No uncontrolled infection PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy See Disease Characteristics Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>essential thrombocythemia</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>